Systems and methods for managing the pH of a dialysate fluid during hemodialysis therapy. The systems and methods adjust dialysate pH and buffer concentration to generate a predetermined total bicarbonate buffer concentration in a dialysate entering a dialyzer.

Systems and methods for managing the pH of a dialysate fluid during hemodialysis therapy. The systems and methods adjust dialysate pH and buffer concentration to generate a predetermined total bicarbonate buffer concentration in a dialysate entering a dialyzer.

The present disclosure relates to a system and a method for determining the dry weight of a patient after dialysis therapy, wherein the patient's blood volume is monitored and blood volume values are output. The blood volume values are recorded and evaluated for a predetermined period of time after reaching an ultrafiltration volume appropriately predetermined for the patient, wherein the dry weight of the patient then is determined on the basis of the rate of change of the blood volume during the predetermined period of time.

The present disclosure relates to a system and a method for determining the dry weight of a patient after dialysis therapy, wherein the patient's blood volume is monitored and blood volume values are output. The blood volume values are recorded and evaluated for a predetermined period of time after reaching an ultrafiltration volume appropriately predetermined for the patient, wherein the dry weight of the patient then is determined on the basis of the rate of change of the blood volume during the predetermined period of time.

The present invention relates to a column comprising a vascular endothelial growth factor (VEGF) dimer molecule, a method for preparing such a column, a VEGF dimer molecule, an expression vector and a recombinant host cell encoding for a VEGF dimer, as well as uses and methods related thereto.

An apparatus (1a) for extracorporeal blood treatment, comprising an infusion control arrangement (8) arranged for infusing a pre-dilution flow rate upstream a blood treatment unit (4) and a post-dilution flow rate downstream the blood treatment unit (4), an ultrafiltration, UF, arrangement (40) arranged for ultrafiltration of a liquid through a semipermeable membrane (7) of the blood treatment unit (4) and a control unit (31). The control unit (31) is configured to configure the infusion control arrangement (8) to obtain a plurality of different configurations of the pre-dilution flow rate and/or post-dilution flow rate. For each of the plurality of different configurations, the control unit (31) is configured to change an operating situation of the UF arrangement (40), to detect a plurality of ultrafiltration flow rate values through the membrane (7) as a function of TMP, on changing said operating situation, and to evaluate an optimal ultrafiltration flow rate value from a comparison of the detected ultrafiltration flow rates. The apparatus (1a) is also configured to estimate a clearance value for a certain solute at the optimal ultrafiltration flow rate value and to evaluate a preferred configuration of the pre-dilution flow rate and/or post-dilution flow rate from a comparison of the corresponding estimated clearance values.

A portable hemodialysis system is provided including a dialyzer, a closed loop blood flow path which transports blood from a patient to the dialyzer and back to the patient, and a closed loop dialysate flow path which transports dialysate through the dialyzer. In addition, the hemodialysis system includes two reservoirs which can be alternately placed in the dialysis flow path using various controllable fluid valves. The weight, and therefore the level of dialysate, of each reservoir is measured by a preferred level sensor having a strain measuring device which includes a load cell and a tilt sensor. The load cell and tilt sensor are electrically connected to a processor for sending force and tilt measurements to the processor. The processor may analyze the tilt measurements to correct for any inaccurate measurements of the load cell caused by the tilt.

A method for performing apheresis of mammals, including humans, is set forth which does not require separation of the blood into plasma or any other portion. Termed whole blood apheresis herein, this advance makes it possible to perform apheresis more quickly and efficiently with less stress for the patient. This application also discloses important advances in apheresis for therapeutic treatments, including treatments for sepsis and AKI using whole blood apheresis, and immunotherapy where targets that interfere with recovery are removed by apheresis and gene-engineered fragments previously removed are reintroduced. Use of selective withdrawal through apheresis expands possible resolutions of illnesses and conditions previously thought to be untreatable.

A hysteroscopic fluid management system includes a saline source with an electrolyte concentration, at least one pressure mechanism for circulating saline to and from a targeted site and through a filter having filter characteristics back to the source, and a controller. The controller provides a saline inflow in a first flow path to the site and a saline outflow in a second flow path from the site through the filter and back to the source at a controlled flow rate. A diagnostic or therapeutic procedure is performed at the site in the presence of the saline. The filter characteristics and the controlled flow rate are selected to (1) cause substantially no change in the electrolyte concentration in the saline, (2) to prevent hemolysis of greater than 5% of filtered red blood cells exposed to the saline, and/or (3) to minimize effect on prothrombin time of plasma exposed to the filter.

A blood purification apparatus that includes a blood purifier, a vascular access flow path, a cleaning solution flow path, and a drainage flow path. The blood purifier has an inner portion divided by a semi-permeable membrane into a first portion and a second portion. The vascular access flow path is connected to the blood purifier and is in communication with the first portion. The cleaning solution flow path is connected to the blood purifier and is in communication with the first portion. The drainage flow path is connected to the blood purifier and is in communication with the second portion. The cleaning solution flow path is provided with a blood pump capable of bidirectionally feeding a fluid. An open-close valve is provided in each of the vascular access flow path and the drainage flow path.